MDM2 regulates vascular endothelial growth factor mRNA stabilization in hypoxia

Molecular and Cellular Biology

Volumn 31, Issue 24, 2011, Pages 4928-4937

  Zhou, Sheng ^a   Gu, Lubing ^b   He, Jing ^b   Zhang, Hailong ^b   Zhou, Muxiang ^b  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; MUTANT PROTEIN; PROTEIN MDM2; PROTEIN P53; SMALL INTERFERING RNA; VASCULOTROPIN;

3' UNTRANSLATED REGION; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL SURVIVAL; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HYPOXIA; NEUROBLASTOMA CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROCESSING; PROTEIN SECRETION; UPREGULATION;

3' UNTRANSLATED REGIONS; BLOTTING, WESTERN; CELL HYPOXIA; CELL LINE, TUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; PLASMIDS; PROTO-ONCOGENE PROTEINS C-MDM2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA PROCESSING, POST-TRANSCRIPTIONAL; RNA STABILITY; RNA, MESSENGER; RNA, SMALL INTERFERING; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 83255186735     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.06085-11     Document Type: Article

References (42)

1. Benjamin, D., and C. Moroni. 2007. mRNA stability and cancer: an emerging link? Expert Opin. Biol. Ther. 7:1515-1529.
2. Bertout, J. A., S. A. Patel, and M. C. Simon. 2008. The impact of O2 availability on human cancer. Nat. Rev. Cancer 8:967-975.
3. Bond, G. L., et al. 2004. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 119:591-602.
4. Cairrao, F., A. S. Halees, K. S. Khabar, D. Morello, and N. Vanzo. 2009. AU-rich elements regulate Drosophila gene expression. Mol. Cell. Biol. 29: 2636-2643.
5. Candeias, M. M., et al. 2008. p53 mRNA controls p53 activity by managing Mdm2 functions. Nat. Cell Biol. 10:1098-1105.
6. Carmeliet, P., and D. Collen. 1999. Role of vascular endothelial growth factor and vascular endothelial growth factor receptors in vascular development. Curr. Top. Microbiol. Immunol. 237:133-158.
7. Chen, C. Y., and A. B. Shyu. 1995. AU-rich elements: characterization and importance in mRNA degradation. Trends Biochem. Sci. 20:465-470.
8. Claffey, K. P., et al. 1998. Identification of a human VPF/VEGF 3' untranslated region mediating hypoxia-induced mRNA stability. Mol. Biol. Cell 9:469-481.
9. Corvi, R., et al. 1995. Non-syntenic amplification of MDM2 and MYCN in human neuroblastoma. Oncogene 10:1081-1086.
10. Datta, M. W., E. Macri, S. Signoretti, A. A. Renshaw, and M. Loda. 2001. Transition from in situ to invasive testicular germ cell neoplasia is associated with the loss of p21 and gain of mdm-2 expression. Mod. Pathol. 14:437-442.
11. Elenbaas, B., M. Dobbelstein, J. Roth, T. Shenk, and A. J. Levine. 1996. The MDM2 oncoprotein binds specifically to RNA through its RING finger domain. Mol. Med. 2:439-451.
12. Ferrara, N., and T. Davis-Smyth. 1997. The biology of vascular endothelial growth factor. Endocr. Rev. 18:4-25.
13. Forsythe, J. A., et al. 1996. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol. Cell. Biol. 16:4604-4613.
14. Ganly, I., et al. 2007. Identification of angiogenesis/metastases genes predicting chemoradiotherapy response in patients with laryngopharyngeal carcinoma. J. Clin. Oncol. 25:1369-1376.
15. Gu, L., et al. 2009. Regulation of XIAP translation and induction by MDM2 following irradiation. Cancer Cell 15:363-375.
16. Haupt, Y., R. Maya, A. Kazaz, and M. Oren. 1997. Mdm2 promotes the rapid degradation of p53. Nature 387:296-299.
17. Ho, Q. T., and C. J. Kuo. 2007. Vascular endothelial growth factor: biology and therapeutic applications. Int. J. Biochem. Cell Biol. 39:1349-1357.
18. Keene, J. D. 2007. RNA regulons: coordination of post-transcriptional events. Nat. Rev. Genet. 8:533-543.
19. Khor, L. Y., et al. 2009. MDM2 and Ki-67 predict for distant metastasis and mortality in men treated with radiotherapy and androgen deprivation for prostate cancer: RTOG 92-02. J. Clin. Oncol. 27:3177-3184.
20. Kim, K. J., et al. 1993. Inhibition of vascular endothelial growth factorinduced angiogenesis suppresses tumour growth in vivo. Nature 362:841-844.
21. Ladanyi, M., et al. 1993. MDM2 gene amplification in metastatic osteosarcoma. Cancer Res. 53:16-18.
22. Lai, Z., D. A. Freedman, A. J. Levine, and G. L. McLendon. 1998. Metal and RNA binding properties of the hdm2 RING finger domain. Biochemistry 37:7005-7015.
23. Leach, F. S., et al. 1993. p53 mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res. 53:2231-2234.
24. Levy, A. P., N. S. Levy, and M. A. Goldberg. 1996. Post-transcriptional regulation of vascular endothelial growth factor by hypoxia. J. Biol. Chem. 271:2746-2753.
25. Levy, N. S., S. Chung, H. Furneaux, and A. P. Levy. 1998. Hypoxic stabilization of vascular endothelial growth factor mRNA by the RNA-binding protein HuR. J. Biol. Chem. 273:6417-6423.
26. Mathew, R., et al. 2002. Alterations in p53 and pRb pathways and their prognostic significance in oesophageal cancer. Eur. J. Cancer 38:832-841.
27. Mayo, L. D., and D. B. Donner. 2001. A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc. Natl. Acad. Sci. U. S. A. 98:11598-11603.
28. Meek, D. W., and U. U. Knippschild. 2003. Posttranslational modification of MDM2. Mol. Cancer Res. 1:1017-1026.
29. Momand, J., D. Jung, S. Wilczynski, and J. Niland. 1998. The MDM2 gene amplification database. Nucleic Acids Res. 26:3453-3459.
30. Momand, J., G. P. Zambetti, D. Olson, D. George, and A. J. Levine. 1992. The MDM-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69:1237-1245.
31. Narasimhan, M., R. Rose, R. Ramakrishnan, J. A. Zell, and A. Rathinavelu. 2008. Identification of HDM2 as a regulator of VEGF expression in cancer cells. Life Sci. 82:1231-1241.
32. Perfumo, C., et al. 2009. MDM2 SNP309 genotype influences survival of metastatic but not of localized neuroblastoma. Pediatr. Blood Cancer 53: 576-583.
33. Plate, K. H., G. Breier, H. A. Weich, and W. Risau. 1992. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 359:845-848.
34. Rayburn, E., R. Zhang, J. He, and H. Wang. 2005. MDM2 and human malignancies: expression, clinical pathology, prognostic markers, and implications for chemotherapy. Curr. Cancer Drug Targets 5:27-41.
35. Shih, S. C., and K. P. Claffey. 1999. Regulation of human vascular endothelial growth factor mRNA stability in hypoxia by heterogeneous nuclear ribonucleoprotein L. J. Biol. Chem. 274:1359-1365.
36. Shweiki, D., A. Itin, D. Soffer, and E. Keshet. 1992. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359:843-845.
37. Shweiki, D., M. Neeman, A. Itin, and E. Keshet. 1995. Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids: implications for tumor angiogenesis. Proc. Natl. Acad. Sci. U. S. A. 92:768-772.
38. Skinner, H. D., J. Z. Zheng, J. Fang, F. Agani, and B. H. Jiang. 2004. Vascular endothelial growth factor transcriptional activation is mediated by hypoxia-inducible factor 1alpha, HDM2, and p70S6K1 in response to phosphatidylinositol 3-kinase/AKT signaling. J. Biol. Chem. 279:45643-45651.
39. Vumbaca, F., K. N. Phoenix, D. Rodriguez-Pinto, D. K. Han, and K. P. Claffey. 2008. Double-stranded RNA-binding protein regulates vascular endothelial growth factor mRNA stability, translation, and breast cancer angiogenesis. Mol. Cell. Biol. 28:772-783.
40. Zhang, L., and R. P. Hill. 2004. Hypoxia enhances metastatic efficiency by up-regulating Mdm2 in KHT cells and increasing resistance to apoptosis. Cancer Res. 64:4180-4189.
41. Zhou, G., et al. 2007. MDM2 promoter SNP309 is associated with risk of occurrence and advanced lymph node metastasis of nasopharyngeal carcinoma in Chinese population. Clin. Cancer Res. 13:2627-2633.
42. Zietz, C., et al. 1998. MDM-2 oncoprotein overexpression, p53 gene mutation, and VEGF up-regulation in angiosarcomas. Am. J. Pathol. 153:1425-1433.